epitalon and ghk cu together V-Hacker combines Epitalon, GHK-Cu, NAD⁺, and synthetic exosomal technology to support skin longevity, hydration, and Epitalon Drawing of Peptide in

K., Cristofaro, V., & Sullivan, M

OASIS trials: establishing effective doses Phase 2 OASIS 1 findings: Tested multiple dose levels: 0.3mg, 0.6mg, 1.2mg, 2.4mg, 4.5mg weekly Duration: 26 weeks Primary endpoint: Weight loss at each dose Dose-response results: 0.3mg weekly: ~4% body weight loss 0.6mg weekly: ~6% body weight loss 1.2mg weekly: ~8% body weight loss 2.4mg weekly: ~10% body weight loss 4.5mg weekly: ~12% body weight loss Key insight: Clear dose-response relationship

BPC-157 in Animal Studies: Promising but Preliminary Multiple preclinical studies have shown encouraging findings: Tendon and ligament healing : Animal models suggest faster recovery after surgical repairs or experimental ruptures ([1], [2])

It is one possible tool among many, not a cure, and it works only alongside sleep, nutrition, and training